ZURICH & NEW YORK--(BUSINESS WIRE)--EffRx Pharmaceuticals SA, a leader in innovative drug delivery technologies that improve efficacy and tolerability of existing compounds, has established a worldwide collaboration with Kadmon Corporation, LLC a global biopharmaceutical company, under which EffRx will generate effervescent formulations of products to be developed by Kadmon in both adult and pediatric orphan indications. Financial terms of the agreement were not disclosed.
“Our collaboration with Kadmon, a world-class biopharmaceutical company, further validates our thesis that there is an acute need for alternative drug delivery methods. Our effervescent technology is an innovative delivery option that provides patients with convenience and reduces pill burden,” said Christer Rosen, EffRx Chairman and Chief Executive Officer.
“Alternative drug delivery strategies can be an important part of treatment success,” said Samuel D. Waksal, Ph.D., Kadmon Chairman and Chief Executive Officer. “We are excited to partner with EffRx to develop formulations of certain therapies aimed at adult and pediatric orphan indications, with the goal of designing treatments that are more tolerable and ensure better treatment compliance. We look forward to describing these programs in detail as they approach the commercial setting.”
About EffRx Pharmaceuticals
EffRx Pharmaceuticals is an innovative specialty pharmaceutical company that exploits its proprietary technology platform to create novel therapeutic entities.
EffRx strives to make existing good medicines better and thereby improve the quality of life of patients. EffRx targets improvements to leading medications, focused on tolerability, absorption, compliance and convenience, thus creating best in class products.
EffRx has established its proprietary pipeline in metabolic bone disease and pediatric medications and is partnering with pharmaceutical companies to create life cycle management opportunities in their portfolios.
About Kadmon Corporation
Kadmon Corporation, LLC, is a global company built on a 21st-century paradigm for the translation of innovative science into treatment. The company currently offers products and services for the treatment and management of liver diseases, and is pioneering novel medicines in areas of other serious disease, including oncology, infectious diseases, immunology and neurodegenerative diseases. Emphasizing emerging concepts in molecular biology and genomics, Kadmon is developing treatments and treatment combinations that target the metabolomics and signaling pathways associated with disease, with the goal of addressing some of today’s most pressing areas of unmet medical need.